An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Author： Stadler Walter M.   Vaughn David J.   Sonpavde Guru   Vogelzang Nicholas J.   Tagawa Scott T.   Petrylak Daniel P.   Rosen Peter   Lin Chia-Chi   Mahoney John   Modi Sanjiv   Lee Peter   Ernstoff Marc S.   Su Wu-Chou   Spira Alexander   Pilz Korinna   Vinisko Richard   Schloss Charles   Fritsch Holger   Zhao Charles   Carducci Michael A.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|7|976-982

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.7, 2014-04, pp. : 976-982

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

By Garcia Jorge A.   Hudes Gary R.   Choueiri Toni K.   Stadler Walter M.   Wood Laura S.   Gurtler Jayne   Bhatia Shailender   Joshi Adarsh   Hozak Rebecca R.   Xu Yihuan   Schwartz Jonathan D.   Thompson John A.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1647-1655

Blackwell Publishing

Access to resources Recommend Favorite

Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer: An Open-Label, Non-Comparative, Multicentre, Phase III Study

By Lundström Eija A.  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 757-765

Adis International

Access to resources Recommend Favorite

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

By Michael Michael   Gibbs Peter   Smith Robert   Godwood Alex   Oliver Stuart   Tebbutt Niall  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 253-261

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

By Doebele Robert C.   Spigel David   Tehfe Mustapha   Thomas Sachdev   Reck Martin   Verma Sunil   Eakle Janice   Bustin Frederique   Goldschmidt Jerome   Cao Dachuang   Alexandris Ekaterine   Yurasov Sergey   Camidge D. Ross   Bonomi Philip  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 883-892

Blackwell Publishing

Access to resources Recommend Favorite

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

By Schilling G.   Bruweleit M.   Harbeck N.   Thomssen C.   Becker K.   Hoffmann R.   Villena C.   Schütte M.   Hossfeld D.   Bokemeyer C.   Wit M.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 166-172

Springer Publishing Company

Access to resources Recommend Favorite